Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous AML lysate and mRNA-loaded dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This is an investigational autologous dendritic cell vaccine developed by the M.D. Anderson Cancer Center for the treatment of acute myeloid leukemia (AML). The therapy involves harvesting a patient's own dendritic cells and loading them with both AML tumor lysate and messenger RNA (mRNA) to present a broad spectrum of leukemia-associated antigens, including Wilms' Tumor-1 (WT1). As a cell-based biologic immunotherapy, it functions as a professional antigen-presenting cell to stimulate and activate autologous cytotoxic T lymphocytes (CTLs) to recognize and eliminate residual leukemia cells. It has been primarily evaluated in Phase 1 clinical settings as a post-consolidation therapy to target minimal residual disease and prevent relapse.
- Other names
- AML mRNA/Lysate DC Vaccineautologous dendritic cells loaded with AML lysate plus mRNAautologous dendritic cells-M.D. Anderson Cancer Center-acute myeloid leukemia
02
Targets
pMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous AML lysate and mRNA-loaded dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous AML lysate and mRNA-loaded dendritic cell vaccine.